

# Scandinavian clinical practice guideline on choice of fluid in resuscitation of critically ill patients with acute circulatory failure

A. Perner<sup>1</sup>, E. Junttila<sup>2</sup>, M. Haney<sup>3</sup>, K. Hreinsson<sup>4</sup>, R. Kvåle<sup>5</sup>, P. O. Vandvik<sup>6</sup> and M. H. Møller<sup>1</sup>

<sup>1</sup>Department of Intensive Care, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>2</sup>Department of Anaesthesiology, Division of Intensive Care, Oulu University Hospital and Department of Anaesthesiology, Tampere University Hospital, Tampere, Finland

<sup>3</sup>Anaesthesiology and Intensive Care Medicine, Umeå University, Umeå, Sweden

<sup>4</sup>Department of Anaesthesiology and Intensive Care Medicine, Landspítali University Hospital, Reykjavik, Iceland

<sup>5</sup>Department of Intensive Care, Haukeland University Hospital, Bergen, Norway

<sup>6</sup>Department of Medicine, Innlandet Hospital Trust-Division Gjøvik, Norway and Norwegian Knowledge Centre for the Health Services, Oslo, Norway

## Correspondence

A. Perner, Department of Intensive Care, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen DK-2100, Denmark  
E-mail: anders.perner@rh.regionh.dk

## Conflict of interests

E. J., M. H., K. H., R. K., P. O. V. and M. H. M. have declared no conflict of interest. A. P. was the sponsor-investigator of the 6S trial, which was supported by B. Braun, and he has received honoraria from Ferring Pharmaceuticals (SC work in a sepsis trial) and LFB S.A. (speakers fee). The Department of Intensive Care, Rigshospitalet receives support for research from CLS Behring, Fresenius Kabi, BioPorto and Cosmed.

## Funding

The task force received methodological and practical support from the Norwegian Knowledge Centre for the Health Services and the Grading of Recommendations Assessment, Development and Evaluation working group, as well as funding from SSAI.

Submitted 12 September 2014; accepted 17 September 2014; submission 12 July 2014.

## Citation

Perner A, Junttila E, Haney M, Hreinsson K, Kvåle R, Vandvik PO, Møller MH. Scandinavian clinical practice guideline on choice of fluid in resuscitation of critically ill patients with acute circulatory failure. *Acta Anaesthesiologica Scandinavica* 2014

doi: 10.1111/aas.12429

An electronic version of this guideline can be accessed at <http://www.ssai.info/guidelines/>

*Acta Anaesthesiologica Scandinavica* (2014)

© 2014 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd

**Background:** The task force on Acute Circulatory Failure of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine produced this guideline with recommendations concerning the use of crystalloid vs. colloid solutions in adult critically ill patients with acute circulatory failure.

**Methods:** Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to grade the quality of evidence and to determine the strengths of the recommendations. As efficacy and harm may vary in different subpopulations of patients with acute circulatory failure, we produced recommendations for general intensive care unit (ICU) patients and those with sepsis, trauma and burn injury.

**Results:** For general ICU patients and those with sepsis, we recommend using crystalloids for resuscitation rather than hydroxyethyl starch and we suggest using crystalloids rather than gelatin and albumin. For patients with trauma we recommend to use crystalloids for resuscitation rather than colloid solutions. For patients with burn injury we provide no recommendations as there are very limited data from randomised trials on fluid resuscitation in this patient population.

**Conclusions:** We recommend using crystalloid solutions rather than colloid solutions for resuscitation in the majority of critically ill patients with acute circulatory failure.

As part of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine's (SSAI) efforts to improve perioperative and intensive care, this clinical practice guideline was produced by the SSAI Acute Circulatory Failure task force. The work was initiated by the Clinical Practice Committee of SSAI.

Acute circulatory failure or circulatory shock is a frequent and life-threatening condition that needs prompt and appropriate care.<sup>1</sup> With either cardiac and/or non-cardiac aetiologies, inadequate cardiac output, altered peripheral vascular tone and/or loss or imbalance in intravascular volume can contribute to limited delivery and uptake of substrates in vital organs. If left untreated, hypotension, hypoperfusion and cellular hypoxia may progress to organ failure and death.

Fluid resuscitation is a mainstay therapy for the non-cardiac causes of acute circulatory failure for patients with sepsis, trauma and burn injury, and in support of the circulation in critically ill patients in general. There is a need for clinical practice guidelines to reflect new evidence concerning the choice of fluid for therapy of acute circulatory failure.<sup>2</sup> This clinical practice guideline is among the first to be produced from our group meeting the new standards for trustworthy guidelines, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (<http://www.gradeworkinggroup.org>).<sup>3-5</sup>

## Methods

### Process

The Clinical Practice Committee of SSAI appointed national members of the guideline task force for Acute Circulatory Failure (the authors of this paper). We invited two colleagues with focused methodological experience in systematic reviews and the GRADE system (P. O. V. and M. H. M.) to help facilitate the work.

The task force identified key clinical questions for fluid resuscitation, vasopressor therapy, inotropic therapy and diagnostics and monitoring to fully cover the management of acute circulatory failure. This is the report of the work on choice of fluid type for critical care resuscitation.

## GRADE

We used the GRADE system for formulating clinical questions, assessing the quality of evidence, generating anticipated absolute effects and for moving from evidence to recommendations.<sup>5</sup> Briefly, clinical questions were formulated in a specific format, which identified the relevant patient population and/or clinical problem (P), the intervention (I) under scrutiny as well as the comparator (C), and patient-important outcomes (O). It is likely that the efficacy and harm of fluids may be context dependent; that is, they can be different for different patient populations, comparator fluids and outcomes. Therefore, we aimed to identify benefits and harms of crystalloid vs. colloid resuscitation in critical care by answering the combination of populations/interventions/comparators/outcomes (PICO) questions outlined in Table 1 amounting to 12 different specific questions in total.

The populations were general intensive care unit (ICU) patients, patients with sepsis, patients with trauma and patients with burn injury. The standard intervention was crystalloid solution for resuscitation fluid. Relevant comparators were hydroxyethyl starch (HES), gelatin or albumin. For the starch solutions, we assessed when possible HES 130/0.38–0.45 (molecular weight/substitution ratio) rather than the older products with higher molecular weight and substitution ratio. The patient outcomes of interest were mortality, use of renal replacement therapy (RRT), acute kidney injury (AKI), bleeding, serious adverse events (SAEs) and length of hospital stay.

We systematically searched PubMed and the Cochrane Library for recently updated systematic reviews of randomised clinical trials (RCTs) comparing crystalloid solutions with colloid solutions. We updated the searches of the identified reviews in April 2014 using the search strategies of these reviews. If we found no systematic review or subgroup analysis in reviews answering specific PICOs, as it was the case for patients with trauma and burn injury, we searched for RCTs in PubMed [free text: 'random\* and (colloid/HES/starch/gelatin/albumin) and (trauma/injur\*/burn/thermal)], and in the recently updated systematic reviews on fluid resuscitation in critically ill patients in general.<sup>2,6-8</sup>

**Table 1** Clinical and PICO questions used to assess evidence relevant to this guideline statement.

Clinical question	PICO question			
	Population (P)	Intervention (I)	Comparator (C)	Outcomes (O)
1. Should crystalloid or colloid solutions be used for resuscitation of acutely ill patients with circulatory failure?	Adult acutely ill patients: <ul style="list-style-type: none"> <li>• General ICU patients</li> <li>• Sepsis</li> <li>• Trauma</li> <li>• Burn injury</li> </ul>	Crystalloid solutions*	Colloid solutions <ul style="list-style-type: none"> <li>• HES</li> <li>• Albumin</li> <li>• Gelatin</li> </ul>	Mortality at longest follow-up Use of renal replacement therapy Acute kidney injury Bleeding Serious adverse events Length of hospital stay

\*Including isotonic saline or balanced salt solutions including Ringer's or Hartman's.

The target populations were adult critically ill patients with acute circulatory failure/shock resuscitated with crystalloid or colloid in a high-dependency setting in hospital, including the emergency department, ICU, operating room or recovery room. We excluded systematic reviews and trials done in patients aged less than 18 years, done in elective surgery, those not comparing crystalloids with colloids (e.g. colloid vs. colloid) and those comparing hypertonic crystalloid solution(s) with colloid. Reviews and trials comparing a crystalloid solution to dextrans or HES with molecular weight or substitution ratio above 130 or 0.45, respectively, were excluded because these colloid solutions are less used.<sup>9</sup>

If we identified trials not included in the systematic reviews we updated the meta-analyses with data from the identified RCTs using Revman 5 (<http://www.tech.cochrane.org/Revman>). If the identified systematic reviews did not provide relevant meta-analyses for our PICOs, we extracted data from relevant RCTs and performed meta-analyses using Revman 5 to obtain pooled effect-estimates for as many of the PICOs as possible.

In keeping with the GRADE methodology, we downgraded the quality of evidence for an intervention (our confidence in the effect-estimates) for identified risks of bias (lack of blinding, or early termination of studies), inconsistency (unexplained heterogeneity), indirectness (e.g. other patient populations or use of surrogate outcomes), imprecision (wide confidence interval around the effect estimate) or publication bias (if identified in the systematic review). The results were presented in summary of finding tables with anticipated relative and absolute effects for the outcomes, together with our confidence in the

effect-estimates using GradePro v. 3.5 (downloaded at <http://www.gradeworkinggroup.org>). Accordingly, the quality of evidence was rated from 'high' to 'very low'.

When moving from evidence to recommendations four factors were considered and integrated: benefits and harms, quality of evidence, values and preferences (of patients or their proxies) and cost considerations. GRADE classifies recommendations as strong when virtually all informed patients would choose the recommended management strategy. Weak recommendations, which reflect a close call between benefits and harms, uncertainty regarding treatment effects, questionable cost-effectiveness, or variability in values and preferences, apply when fully informed patients would choose different management strategies.<sup>5,10</sup>

The recommendations were agreed upon by the group. We specified in advance that if total agreement could not be obtained, the group would vote; 2/3 of the votes were needed to issue a strong recommendation. Strong recommendations were given the wording 'we recommend' and weak recommendations 'we suggest'. If dissenting opinions occurred for a specific recommendation, they were included in the text for clarification.

## Results

The results and recommendations based on the PICOs are presented below, in Table 2 and in the summary of finding tables given in the Supporting information. All members of the guideline group agreed upon all of the recommendations.

**Table 2** Key recommendations and quality of evidence.

	Strength of the recommendation	Benefits and harms	Quality of evidence Reason(s) for downgrading	Comments
<b>Fluid resuscitation of general ICU patients</b>				
1. We recommend that crystalloids are used for resuscitation in general ICU patients rather than HES	Strong	An updated meta-analysis of crystalloid vs. HES in critically ill patients showed clear benefit of crystalloids when balancing all patient-important outcomes, including mortality	Moderate due to risk of bias	
2. We suggest that crystalloids are used for resuscitation in general ICU patients rather than albumin	Weak	An updated meta-analysis of crystalloids vs. albumin in critically ill patients showed no difference in mortality or in other important outcomes	Moderate due to risk of bias	Albumin is a blood product and a limited and costly resource
3. We suggest that crystalloids are used for resuscitation in general ICU patients rather than gelatin	Weak	An updated meta-analysis of crystalloids vs. gelatin in critically ill patients showed no difference in mortality	Very low due to risk of bias and imprecision	Benefits and harms of gelatin are largely unknown, but they have been associated with increased risk of acute kidney injury and bleeding in observational studies
<b>Fluid resuscitation of patients with sepsis</b>				
1. We recommend that crystalloids are used for resuscitation in patients with sepsis rather than HES.	Strong	In two recently updated systematic meta-analyses of crystalloid vs. HES in critically ill septic patients, HES increased long-term (> 28 days) mortality, use of RRT and rates SAEs compared to crystalloids	Moderate due to imprecision	
2. We suggest that crystalloids are used for resuscitation in patients with sepsis rather than albumin.	Weak	A meta-analysis of data from the SAFE and ALBIOS trials showed no benefit or harm from albumin compared to saline	Low due to risk of bias	Albumin is a blood product and a limited and costly resource
3. We suggest that crystalloids are used for resuscitation in patients with sepsis rather than gelatin.	Weak	No meta-analyses or RCTs exist of crystalloids vs. gelatin in patients with sepsis	Very low due to lack of RCTs and meta-analyses	Benefits and harms of gelatin are largely unknown, and they have been associated with increased risk of acute kidney injury and bleeding in observational studies
<b>Fluid resuscitation of patients with trauma</b>				
We recommend that crystalloids are used for resuscitation in patients with trauma rather than colloids.	Strong	A meta-analysis of data of existing RCTs in patients with trauma showed that colloid resuscitation was associated with increased risk of death	Very low due to risk of bias and imprecision	
<b>Fluid resuscitation of patients with burn</b>				
	No recommendation	Very limited data from RCTs	Very low due to risk of bias and imprecision	We refrain from giving any recommendations because of the very low level of evidence

### A. Fluid resuscitation of general ICU patients

1. We recommend that crystalloids are used for resuscitation in general ICU patients rather than HES (strong recommendation and moderate quality of the evidence).

The rationale is that an updated meta-analysis of crystalloid vs. HES showed clear benefit of crystalloids when balancing all patient-important outcomes, including mortality, in critically ill patients (Table S1A).<sup>7</sup> The results are supported by the meta-analyses comparing HES to any other comparators<sup>2,6</sup> and those of a large, high-quality RCT that compared 0.9% NaCl with 6% HES 130/0.4 in 7000 general ICU patients with signs of hypovolaemia.<sup>11</sup> The results of the latter trial indicated no differences in survival or hospital length of stay between the intervention groups, but the HES group had increased use of RRT and increased adverse events, mainly pruritus. Another recently published large RCT, the CRISTAL trial,<sup>12</sup> compared any crystalloid to any colloid solution in ICU patients with shock. The results indicated that colloids (mainly HES) vs. crystalloids (mainly saline) improved 90-day mortality, which was a secondary outcome measure. However, the trial had high risk of bias in several domains (unblinded, uncertain allocation concealment and baseline imbalance)<sup>13</sup> and the results differed from those of the high-quality trials mentioned above. In an accompanying editorial, the editor argued for cautious interpretation of these findings and that crystalloid should be the first line fluid in patients with shock.<sup>14</sup> Given the high risk of bias in CRISTAL, we did not take these data into consideration. Based on the included data we recommend that crystalloid solutions rather than HES are used for resuscitation in general ICU patients. The binding decision from European Commission also states that HES should not be used in critically ill patients.\*

2. We suggest that crystalloids are used for resuscitation in general ICU patients rather than albumin (weak recommendation and moderate quality of the evidence).

The rationale is that an updated meta-analysis of albumin vs. crystalloids in critically ill patients

showed no difference in mortality or in other outcomes (Table S1B).<sup>7</sup> The results are supported by those of a large, high-quality RCT, the SAFE trial, which compared 0.9% NaCl with 4% albumin in 7000 general ICU patients with signs of hypovolaemia.<sup>15</sup> In that trial none of the outcome measures differed between the two intervention groups, including mortality, use of RRT and hospital length of stay (Table S1B). No cost minimisation analysis was made in SAFE, but albumin is a blood product and as such a limited resource and its cost is much higher than that of crystalloids. Therefore, we suggest using the latter in general ICU patients.

3. We suggest that crystalloids are used for resuscitation in general ICU patients rather than gelatin (weak recommendation and very low quality of the evidence).

The rationale is that the updated meta-analysis of gelatin vs. crystalloids in critically ill patients showed no difference in mortality (Table S1C).<sup>7</sup> However, there were few events in the trials included and the pooled effect-estimate was imprecise. Therefore the benefits and harms of gelatin are largely unknown in these patients, but they have been associated with increased risk of AKI and bleeding.<sup>16,17</sup> These observations are supported by data from an updated meta-analysis of gelatin vs. albumin/crystalloid.<sup>18</sup> As mentioned above, there appears to be no benefit of other colloid solutions in critically ill patients in general, and therefore we suggest that gelatin is not used in these patients. However, the quality of the evidence is very low for this suggestion.

### B. Fluid resuscitation of patients with sepsis

1. We recommend that crystalloids are used for resuscitation in patients with sepsis rather than HES (strong recommendation and moderate quality of the evidence).

The rationale is based on two recently updated systematic reviews on patients with sepsis,<sup>19,20</sup> which included most of the same RCTs (we chose to use data from the one including most trials – nine trials with 3456 patients also including SAEs as an outcome vs. six trials with 3033 patients) (Table S2A). The systematic review we report included two RCTs that used albumin as comparator,<sup>19</sup> however few patients received

\*[http://www.ec.europa.eu/health/documents/community-register/2013/20131219127286/dec\\_127286\\_en.pdf](http://www.ec.europa.eu/health/documents/community-register/2013/20131219127286/dec_127286_en.pdf)




Fig. 1. Forest plot of (A) all-cause mortality and (B) renal replacement therapy in randomised trials of crystalloid vs. albumin for resuscitation of patients with sepsis. Size of squares for risk ratio reflects weight of trial in pooled analyses. Horizontal bars represent 95% confidence intervals.

albumin and these contributed with few events and only in the outcomes mortality and SAEs. There was overall heterogeneity among trial results, but this was balanced by the pre-defined subgroup analysis of trials with low risk of bias. These trials also had follow-up for mortality for more than 28 days, which is important because the difference in mortality between patients assigned to HES vs. crystalloid was observed beyond day 28 in one trial.<sup>21</sup> In patients with sepsis, HES 130/0.38–0.45 increased long-term (> 28 days) mortality compared to crystalloids (Table S2A). In addition, the use of RRT was increased and more patients had SAEs with HES compared to crystalloids (Table S2A). The binding decision from the European Commission also states that HES should not be used in patients with sepsis.\*

2. We suggest that crystalloids are used for resuscitation in patients with sepsis rather than albumin (weak recommendation and moderate quality of the evidence).

We identified a recently updated systematic review including 17 RCTs.<sup>22</sup> In 12 of the trials included in that review, the comparator was a synthetic colloid, three trials were in children, and one in ARDS patients. As the SAFE trial was the only RCT comparing albumin to crystalloid that

included adults with sepsis, we base our suggestion on data from SAFE<sup>15</sup> and the recently published ALBIOS trial.<sup>23</sup> In SAFE, the 1218 included patients with severe sepsis were analysed as pre-defined subgroup, but sepsis was not a stratification variable at randomisation. In the subgroup analysis of these patients there was a trend towards lower 28-day mortality with albumin vs. saline. In the ALBIOS trial, 1818 patients with severe sepsis were randomised to 20% albumin vs. saline, but there were no differences in 28-day mortality, which was the primary outcome, or in any of the secondary outcome measures.<sup>23</sup> Pooling the data from the SAFE and ALBIOS trials showed no benefit or harm from albumin compared with saline (Fig. 1 and Table S2B). Economic analyses were not made in SAFE or ALBIOS, but albumin is a limited and costly resource. Emerging data from RCTs in adults with sepsis will hopefully clarify the indications for albumin. Until then we suggest not to use albumin for resuscitation in adults with sepsis.

3. We suggest that crystalloids are used for resuscitation in patients with sepsis rather than gelatin (weak recommendation and very low quality of the evidence).

The rationale is based on a recently updated systematic review where no RCTs could be





Fig. 2. Forest plot of all-cause mortality in randomised trials of crystalloid vs. colloid solutions for resuscitation of patients with trauma.<sup>11,15,34-39</sup> The trial results were sub-grouped based on the colloid solution (albumin, starch and gelatin) used in the trials. Size of squares for risk ratio reflects weight of trial in pooled analyses. Horizontal bars represent 95% confidence intervals.

included for adult patients with sepsis.<sup>18</sup> We have updated the search and also found no RCTs in adult patients with sepsis comparing gelatin to crystalloids. Therefore the benefits and harms of gelatin are unknown in patients with sepsis. As noted above, gelatin has been associated with increased risk of kidney failure and bleeding.<sup>16,17</sup> The results from trials assessing other colloids indicate that there are little, if any, differences in fluid volumes and circulatory parameters between patients with sepsis resuscitated with colloid vs. crystalloid solutions.<sup>21,24</sup> Therefore, we recommend that if clinicians want to use gelatin in sepsis, this should only be in the context of an RCT of sufficient size to detect side effects, a notion supported by the European Society of Intensive Care Medicine task force on colloids.<sup>25</sup>

### C. Fluid resuscitation of patients with trauma

1. We recommend that crystalloids are used for resuscitation in patients with trauma rather than colloids (strong recommendation and low quality of the evidence).

We did not identify an updated systematic review of patients with trauma. In the updated, large systematic reviews of critically ill patients we found RCTs examining crystalloid vs. colloid solutions in trauma. Our own meta-analysis of data of the RCTs in patients with trauma showed that colloid resuscitation was associated with an increased risk of death [Fig. 2 and (Table S3A-C)]. There were not sufficient data to analyse the other outcome measures.



**Fig. 3.** Forest plot of all-cause mortality in randomised trials of crystalloid vs. colloid solutions for resuscitation of patients with burn injury.<sup>26–28</sup> The trial results were sub-grouped based on the colloid solution (albumin and starch) used in the trials. Size of squares for risk ratio reflects weight of trial in pooled analyses. Horizontal bars represent 95% confidence intervals.

#### D. Fluid resuscitation of patients with burn injury

For patients with burn injury we could not find updated systematic reviews and we only identified three small RCTs that were relevant for this clinical question.<sup>26–28</sup> Two of these trials were on albumin vs. Ringer's lactate and both were small (total  $n = 79$  and  $n = 42$ ) and the larger trial had high risk of bias (lack of allocation concealment and blinding).<sup>26</sup> The third trial assessed 48 patients randomised to HES 130/0.40 vs. Ringer's lactate and showed no benefit or harm of HES,<sup>28</sup> but the interpretation is hampered by the small sample size (imprecision). Based on the very limited amount of data (Fig. 3 and Table S4A–C) we refrain from giving any recommendations or suggestions on choice of resuscitation fluid for burn patients. However, we strongly recommend that clinicians who continue to use colloid solutions in patients with burn injury do so in the context of high quality RCTs given the limited effects and harms observed with colloids in other patient groups (ungraded). And clinicians should be aware of the binding decision from the European Commission, which states that HES should not be used in patients with burn injury.\*

#### Discussion

This guideline on fluid resuscitation has been produced following the recently, updated, high-quality meta-analyses comparing crystalloids with colloids.<sup>2,6,7,19</sup> In addition we meta-analysed data from RCTs in several patient groups to obtain a base for moving from evidence to recommendations or suggestions for as many of the PICO questions as possible. We have issued several strong recommendations favouring crystalloids over colloids in all patient groups. This was based on overall low confidence of benefit from colloid resuscitation, confidence of harm caused by the synthetic colloids (high confidence for HES and low for gelatin) and high cost of albumin, which is also a limited resource. For patients with burn injury, we considered the quality of the evidence to be very low and chose not to issue recommendations for these patients. Patients with burn injury likely represent a specific entity because of the massive capillary leak and therefore the results from the other patient categories may be less applicable to these patients. It is our impression that colloid solutions, albumin in particular, are part of burn resuscitation in clinical practice. Therefore, high-quality trials are urgently needed

in patients with burn injury to ensure that this practice is cost-effective and without harm. The use of HES, on the other hand, is now restricted in patients with burn injury by EU legislation.

Our recommendation against the three types of colloids, albumin, HES and gelatin, may result in increased use of dextrans<sup>29,30</sup> or the development of new types of colloids. We believe that clinicians who would consider using dextrans or other types of colloids should do so only in the context of RCTs. The likelihood that dextrans or other colloids would benefit critically ill patients is low given the lack of benefit of albumin. In addition the risk of harm by dextrans, in particular, is eminent because they have been associated with AKI and bleeding.<sup>31,32</sup>

The strengths of our guideline include the application of new standards for trustworthy guidelines and the use of the GRADE methodology, which ensured a systematic and transparent process. The limitations include the reliance upon recently updated systematic reviews for the majority of recommendations. In these, there was no subgrouping of patients based on indications for fluid therapy, most likely because no single indications are supported by high-quality data. We did several meta-analyses, but the number of included RCTs was small, which is a limitation in the evidence base not the guideline per se. We did not include all patient-important outcome measures (e.g. quality of life), because we, a priori, found it less likely to find data from meta-analyses or RCTs on these outcomes. To our knowledge there is only one report on data on quality of life of patients randomised to different types of fluids.<sup>33</sup> Bias may have influenced the results as the chair of the task force was the principal investigator of the 6S trial,<sup>21</sup> which showed harm from HES in sepsis. However, all members of the group formed and agreed upon all recommendations and suggestions in this guideline, making it less likely that bias influenced the results and recommendations.

In conclusion, we recommend using crystalloids for resuscitation of critically ill adult patients including general ICU patients and those with sepsis or trauma. We refrain from giving any recommendations or suggestions on choice of resuscitation fluid for patients with burn injury, because of the very low quality of evidence in these patients. If resuscitation using colloids is to

continue, high-quality trials should be performed to ensure patient safety and overall benefit for patients and society.

## References

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. *Intensive Care Med* 2012; 2013: 165–228.
2. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. *Intensive Care Med* 2013; 39: 558–68.
3. Laine C, Taichman DB, Mulrow C. Trustworthy clinical guidelines. *Ann Intern Med* 2011; 154: 774–5.
4. Qaseem A, Forland F, Macbeth F, Ollenschlager G, Phillips S, Van der Wees P. Guidelines International Network: toward international standards for clinical practice guidelines. *Ann Intern Med* 2012; 156: 525–31.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336: 924–6.
6. Zarychanski R, Bou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. *JAMA* 2013; 309: 678–88.
7. Perel P, Roberts I, Ker K. Colloids vs. crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev* 2013; (2): CD000567.
8. Roberts I, Blackhall K, Alderson P, Bunn F, Schierhout G. Human albumin solution for resuscitation and volume expansion in critically ill patients. *Cochrane Database Syst Rev* 2011; (11): CD001208.
9. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J. Resuscitation fluid use in critically ill adults: an

- international cross-sectional study in 391 intensive care units. *Crit Care* 2010; 14: R185.
10. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, Crowther M, Vandvik PO, Eikelboom JW, McDonagh MS, Lewis SZ, Gutterman DD, Cook DJ, Schunemann HJ. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141: 53S–70S.
  11. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med* 2012; 367: 1901–11.
  12. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, Preiser JC, Outin H, Troche G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Regnier J, Abroug F, Berger P, Clec'h C, Cousson J, Thibault L, Chevret S. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. *JAMA* 2013; 310: 1809–17.
  13. Perner A, Haase N, Wetterslev J. Mortality in patients with hypovolemic shock treated with colloids or crystalloids. *JAMA* 2014; 311: 1067.
  14. Seymour CW, Angus DC. Making a pragmatic choice for fluid resuscitation in critically ill patients. *JAMA* 2013; 310: 1803–4.
  15. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; 350: 2247–56.
  16. Bayer O, Reinhart K, Kohl M, Kabisch B, Marshall J, Sakr Y, Bauer M, Hartog C, Schwarzkopf D, Riedemann N. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. *Crit Care Med* 2012; 40: 2543–51.
  17. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Innerhofer P. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. *Anesth Analg* 2007; 105: 905–17, table.
  18. Thomas-Rueddel DO, Vlasakov V, Reinhart K, Jaeschke R, Rueddel H, Hutagalung R, Stacke A, Hartog CS. Safety of gelatin for volume resuscitation—a systematic review and meta-analysis. *Intensive Care Med* 2012; 38: 1134–42.
  19. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38–0.45 vs. crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. *BMJ* 2013; 346: f839.
  20. Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. *Intensive Care Med* 2013; 39: 811–22.
  21. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J. Hydroxyethyl starch 130/0.42 vs. Ringer's acetate in severe sepsis. *N Engl J Med* 2012; 367: 124–34.
  22. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. *Crit Care Med* 2011; 39: 386–91.
  23. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L. Albumin replacement in patients with severe sepsis or septic shock. *N Engl J Med* 2014; 370: 1412–21.
  24. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. *Intensive Care Med* 2011; 37: 86–96.
  25. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. *Intensive Care Med* 2012; 38: 368–83.
  26. Goodwin CW, Dorethy J, Lam V, Pruitt BA Jr. Randomized trial of efficacy of crystalloid and colloid resuscitation on hemodynamic response and lung water following thermal injury. *Ann Surg* 1983; 197: 520–31.

27. Cooper AB, Cohn SM, Zhang HS, Hanna K, Stewart TE, Slutsky AS. Five percent albumin for adult burn shock resuscitation: lack of effect on daily multiple organ dysfunction score. *Transfusion* 2006; 46: 80–9.
28. Bechir M, Puhan MA, Fasshauer M, Schuepbach RA, Stocker R, Neff TA. Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial. *Crit Care* 2013; 17: R299.
29. Torgersen C, Dunser MW, Schmittinger CA, Pettila V, Ruokonen E, Wenzel V, Jakob SM, Takala J. Current approach to the haemodynamic management of septic shock patients in European intensive care units: a cross-sectional, self-reported questionnaire-based survey. *Eur J Anaesthesiol* 2011; 28: 284–90.
30. FLUIDS study investigators for the Scandinavian Critical Care Trials Group. Preference for colloid use in Scandinavian intensive care units. *Acta Anaesthesiol Scand* 2008; 52: 750–8.
31. Brooks D, Okeefe P, Buncke HJ. Dextran-induced acute renal failure after microvascular muscle transplantation. *Plast Reconstr Surg* 2001; 108: 2057–60.
32. Hvidt LN, Perner A. High dosage of dextran 70 is associated with severe bleeding in patients admitted to the intensive care unit for septic shock. *Dan Med J* 2012; 59: A4531.
33. Wittbrodt P, Haase N, Butowska D, Winding R, Poulsen JB, Perner A. Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial. *Crit Care* 2013; 17: R58.
34. Lowe RJ, Moss GS, Jilek J, Levine HD. Crystalloid vs colloid in the etiology of pulmonary failure after trauma: a randomized trial in man. *Surgery* 1977; 81: 676–83.
35. Lucas CE, Weaver D, Higgins RF, Ledgerwood AM, Johnson SD, Bouwman DL. Effects of albumin vs. non-albumin resuscitation on plasma volume and renal excretory function. *J Trauma* 1978; 18: 564–70.
36. Metildi LA, Shackford SR, Virgilio RW, Peters RM. Crystalloid vs. colloid in fluid resuscitation of patients with severe pulmonary insufficiency. *Surg Gynecol Obstet* 1984; 158: 207–12.
37. Shah DM, Browner BD, Dutton RE, Newell JC, Powers SR Jr. Cardiac output and pulmonary wedge pressure. Use for evaluation of fluid replacement in trauma patients. *Arch Surg* 1977; 112: 1161–8.
38. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). *Br J Anaesth* 2011; 107: 693–702.
39. Wu JJ, Huang MS, Tang GJ, Kao WF, Shih HC, Su CH, Lee CH. Hemodynamic response of modified fluid gelatin compared with lactated ringer's solution for volume expansion in emergency resuscitation of hypovolemic shock patients: preliminary report of a prospective, randomized trial. *World J Surg* 2001; 25: 598–602.

### Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

**Table S1.** (A) Question: Should crystalloids or HES be used for acute circulatory failure in general ICU patients? (B) Question: Should crystalloids or albumin be used for acute circulatory failure in general ICU patients? (C) Question: Should crystalloids or gelatin be used for acute circulatory failure in general ICU patients?

**Table S2.** (A) Question: Should crystalloids or HES be used for acute circulatory failure in patients with sepsis? (B) Question: Should crystalloids or albumin be used for acute circulatory failure in patients with sepsis? (C) Question: Should crystalloids or gelatin be used for acute circulatory failure in patients with sepsis?

**Table S3.** (A) Question: Should crystalloids or HES be used for acute circulatory failure in patients with trauma? (B) Question: Should crystalloids or albumin be used for acute circulatory failure in patients with trauma? (C) Question: Should crystalloids or gelatin be used for acute circulatory failure in patients with trauma?

**Table S4.** (A) Question: Should crystalloids or HES be used for acute circulatory failure in patients with burn? (B) Question: Should crystalloids or albumin be used for acute circulatory failure in patients with burn? (C) Question: Should crystalloids or gelatin be used for acute circulatory failure in patients with burn?